52 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 52 of 52 clinical reviews.
A rigorous side-by-side comparison of four landmark statin trials across primary and secondary prevention populations, matched on absolute risk reduction, NNT, mortality benefit, and LDL-C lowering magnitude.
A guide covering how ACE inhibitors and ARBs raise potassium, who is at highest risk, how to monitor, and what to do when levels rise, plus coverage of statin myopathy, anticoagulant bleeding risk, and beta-blocker bradycardia.
A guide to amlodipine covering mechanism, dosing, side effects, drug interactions, and how it fits alongside atorvastatin, rosuvastatin, simvastatin, and ezetimibe in a cardiometabolic treatment plan.
A clinical breakdown of anticoagulant bleeding risk, including DOAC vs. warfarin data, risk scoring tools, and how to manage bleeding events on blood thinners.
A guide to apixaban (Eliquis) for stroke and clot prevention alongside statins (atorvastatin, rosuvastatin, simvastatin) and ezetimibe for LDL cholesterol lowering, covering mechanisms, dosing principles, interactions, and how these drug classes are used together.
ApoB outperforms LDL-C as a cardiovascular risk predictor in patients with metabolic syndrome, diabetes, or hypertriglyceridemia. The HealthRX.com Medical Team argues clinicians should order it routinely and stop waiting for payers to lead.
ApoB counts every atherogenic particle in your blood. LDL-C only estimates cholesterol mass. Learn which marker predicts cardiovascular risk more accurately, when each test is ordered, and how statins, bempedoic acid, and PCSK9 inhibitors affect both numbers.
A look at whether statin users need CoQ10 supplementation, what the evidence shows about statin-associated muscle symptoms, and when a clinician might actually recommend it.
A guide to atorvastatin (Lipitor) covering mechanism, doses from 10 mg to 80 mg, LDL reduction data, side-effect profile, and head-to-head comparisons with rosuvastatin (Crestor), simvastatin (Zocor), ezetimibe (Zetia), and bempedoic acid (Nexletol).
A guide to atrial fibrillation covering diagnosis, stroke risk, rate vs. rhythm control, anticoagulation, and its overlap with hypertension, metabolic syndrome, hyperlipidemia, and HFpEF.
Evidence-based guide to antihypertensive medications that preserve exercise capacity, VO2max, and athletic performance while effectively lowering blood pressure.
Beta blockers lower heart rate by design, but bradycardia becomes a clinical problem when the rate drops too far. Learn the thresholds, drug interactions, and management steps backed by trial data.
Bisoprolol pairs safely with atorvastatin or rosuvastatin, addressing heart rate and lipid risk together. See dosing, interactions, and monitoring guidance.
180/120 mmHg is a hypertensive crisis. Learn AHA symptoms that mean call 911 vs same-day care, and why BP drops slowly in an emergency.
A guide to cardiometabolic disease in older adults, covering cardiovascular risk, type 2 diabetes, metabolic syndrome, GLP-1 therapies, hormone changes in women, gestational diabetes, and exercise physiology in aging athletes.
A guide to cardiometabolic health in women, including PCOS, pregnancy, gestational diabetes, menopause, REDs, screening, and treatment choices.
A comprehensive clinical guide to cardiometabolic health covering risk factors, biomarkers, lifestyle interventions, GLP-1 medications, and evidence-based targets from major trials and guidelines.
Carvedilol blocks alpha-1 and beta receptors; metoprolol succinate is beta-1 selective. Both cut heart failure mortality by about 34-35% in trials.
A guide to coronary artery disease covering atherosclerosis, risk factors, hypertension staging, hyperlipidemia, metabolic syndrome, HFpEF, diagnostic tests, and evidence-based treatment options.
A clinical breakdown of PCSK9 inhibitor costs, including evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). Covers list prices, net prices, insurance coverage, patient assistance programs, and how these drugs compare to generic statins.
Statins slightly raise new-onset diabetes risk in predisposed patients, but cardiovascular benefits outweigh this risk for most people. Evidence-based analysis of statin-diabetes link, CoQ10, apoB targets, and BP meds for athletes.
A clinical comparison of apixaban (Eliquis) and rivaroxaban (Xarelto) covering bleeding risk, dosing, renal dosing, reversal agents, drug interactions, and cost for AF, DVT, and PE indications.
A guide to ezetimibe (Zetia): mechanism of action, LDL reduction data, side-effect profile, and head-to-head comparisons with atorvastatin, rosuvastatin, simvastatin, and bempedoic acid.
A comprehensive clinical guide to familial hypercholesterolemia covering genetic basis, LDL thresholds, statin dosing, PCSK9 inhibitors, and connections to hypertension, metabolic syndrome, and heart failure with preserved EF.
A detailed breakdown of generic statin costs, PCSK9 inhibitor pricing, and inclisiran expenses. Compare atorvastatin, rosuvastatin, and simvastatin prices with and without insurance.
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases. Learn how it differs from HFrEF, how metabolic syndrome drives it, and which treatments have the strongest evidence.
A guide to hydrochlorothiazide covering mechanism, dosing, side effects, drug interactions, and how it fits alongside statins like atorvastatin, rosuvastatin, and ezetimibe in a cardiometabolic treatment plan.
A complete clinical guide to inclisiran (Leqvio), a twice-yearly PCSK9 siRNA injection, compared with atorvastatin, rosuvastatin, simvastatin, and ezetimibe for LDL-C lowering and cardiovascular risk reduction.
Inclisiran (Leqvio) costs about $3,250 per injection, roughly $6,500 per year. Covered under Medicare Part B, with co-pay assistance available for eligible patients.
Carvedilol is not a statin. It's a beta-blocker for heart failure and hypertension, often taken with statins like atorvastatin for full cardiometabolic care.
Vascepa (icosapent ethyl) costs $300-400/month without insurance, though generic versions are now much cheaper. We break down REDUCE-IT trial data, the mineral-oil placebo controversy, insurance and generic pricing, and which patients the evidence actually supports.
Niacin raises HDL and cuts triglycerides, but AIM-HIGH and HPS2-THRIVE found no added heart benefit over statins like Lipitor, plus more side effects.
A clinical comparison of lisinopril (ACE inhibitor) and losartan (ARB) covering mechanism, efficacy, side effects, organ-protection data, and how cardiometabolic context, ApoB, statins, anticoagulants, and beta-blockers, shapes the choice.
A guide to lisinopril, atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin (Zocor), and ezetimibe (Zetia): how each drug works, what the trials show, dosing, side effects, and how they fit together in a cardiometabolic treatment plan.
A guide to losartan covering mechanism, dosing, side effects, drug interactions, and how it fits alongside atorvastatin, rosuvastatin, simvastatin, and ezetimibe in a complete cardiometabolic treatment plan.
Learn what metabolic syndrome is, how it is diagnosed using ATP III and IDF criteria, how it relates to hypertension, hyperlipidemia, and heart failure, and which lifestyle and pharmacologic treatments have the strongest clinical evidence.
A guide to metoprolol (Lopressor, Toprol-XL), covering FDA-approved uses, dosing for hypertension and heart failure, side effects, and how it compares with statins like atorvastatin, rosuvastatin, and simvastatin in a complete cardiometabolic regimen.
Bempedoic acid inhibits ATP-citrate lyase to lower LDL-C 21-24% alone or 36-38% with ezetimibe (Nexlizet), cutting MACE 13% in statin-intolerant patients.
Nexlizet (bempedoic acid) lowers LDL-C 18-25%, less than statins' 30-55%, but cuts CV events per CLEAR Outcomes for statin-intolerant patients.
A clinical overview of GLP-1 receptor agonist therapy across key patient populations including type 2 diabetes, older adults, women, and pregnancy considerations.
A clinical comparison of PCSK9 inhibitors (evolocumab, alirocumab) versus high-intensity statins (rosuvastatin, atorvastatin) for LDL reduction, cardiovascular outcomes, and patient selection.
A guide to cardiometabolic conditions in pregnancy, covering gestational diabetes management, GLP-1 receptor agonist safety, glucose targets, and long-term cardiovascular risk after delivery.
A guide to rivaroxaban (Xarelto): approved indications, dosing by indication, bleeding risks, drug interactions with statins like atorvastatin and rosuvastatin, and what the ROCKET AF and EINSTEIN trials actually showed.
Evidence-based analysis of statin therapy for adults over 40, including USPSTF guidelines, ApoB targets, risk calculators, and when medication is truly warranted versus lifestyle alone.
A guide to simvastatin (Zocor) covering mechanism, doses, myopathy risk, drug interactions, and head-to-head comparisons with atorvastatin, rosuvastatin, ezetimibe, and bempedoic acid.
A guide to spironolactone for blood pressure control, including how it compares with atorvastatin, rosuvastatin, simvastatin, and ezetimibe in a full cardiometabolic treatment plan.
A statin dose equivalence chart with LDL-lowering intensity tiers, switching protocols, and guidance on titrating blood pressure meds and anticoagulants after a statin change.
A guide to statin myopathy covering muscle pain grading, CK thresholds, drug interactions, rechallenge protocols, and when to switch to alternative lipid-lowering therapy.
A guide to switching anticoagulants safely, including warfarin-to-DOAC transitions, DOAC-to-DOAC switches, bridging protocols, INR timing, statin dose equivalence, and blood pressure medication titration during anticoagulation changes.
Vascepa isn't a statin swap for Lipitor. Added at 4g/day to statin therapy, it cut MACE by 25% in REDUCE-IT by targeting residual triglycerides.
Elevated lipoprotein(a) is a genetically determined cardiovascular risk factor. Learn what high Lp(a) levels mean, how they affect heart disease risk, and what treatment options exist.
Learn what a good apolipoprotein B (ApoB) level is, why it matters more than standard cholesterol panels, and how to lower it with lifestyle changes, statins, and other therapies.